Genmab A/S GMAB 深 沪
已收盘 07-02 16:00:00 美东时间
28.515
+0.875
+3.17%
华盛通- 最 高28.78
- 今 开28.14
- 成交量 141.50万股
- 最 低 28.075
- 昨 收 27.64
- 总市值 1750.64万
- 52周最高 35.43
- 市盈率 静 18.51
- 换手率 0.23%
- 52周最低 20.995
- 委 比 75.27%
- 总股本 0.01亿
- 历史最高 49.07
- 量 比 0.78
- 振 幅 2.55%
- 历史最低 16.24
- 每 手 1
- 风险率 3.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amazon To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Mizuho raised the price target for Robinhood Markets Inc (NASDAQ:HOOD) from $115 to $130. Mizuho analyst Dan D...
07-02 19:41
HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $38 to $40.
07-02 19:05
William Blair updates conviction list: Oracle in, Meta out and more
William Blair added Oracle (ORCL), American Express (AXP), Ecolab (ECL), Comfort Systems USA (FIX), Boot Barn (BOOT), LifeStance Health (LFST), Genmab (GMAB), Silence Therapeutics (SLN), Tyra Bioscien...
07-01 19:26
Genmab与艾伯维淋巴瘤试验达成主要终点 分析师看好更大市场机遇
Genmab公布复发淋巴瘤项目EPCORE DLBCL-4三期临床取得积极结果。 分析师指出该结果具备适应症拓展价值，将为公司带来未来增长潜力。 译文内容由第三...
07-01 00:37
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity
Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relap...
07-01 00:31
艾伯维与Genmab合作开发的血液癌症药物具备竞争优势
美国银行分析师发布研报指出，艾伯维与Genmab合作开发的血癌药物Epkinly在淋巴瘤后期临床试验中表现具备竞争力，其作为弥漫大B细胞淋巴瘤二线治疗的联合疗法...
06-30 23:26
Market-Moving News for June 30th
AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected Q4 financial results. GMAB: 8% | Genmab shares are trading higher after the company announced topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial met its primary objective. CNXC: -25%...
06-30 19:13
Genmab淋巴瘤疗法临床试验达成目标 股价上涨
丹麦生物科技公司Genmab与合作伙伴艾伯维（AbbVie）联合开发的淋巴瘤联合用药方案在后期临床试验中达成主要终点，消息公布后相关标的股价出现异动。 关键交易...
06-30 18:09
分析师解读医疗健康企业：Genmab（GMAB）与Hinge Health, Inc. A类股（HNGE）
医疗保健领域近期获两名分析师分别对Genmab（GMAB）、Hinge Health, Inc. A类股（HNGE）发布看多评级。 核心评级与数据： 富国银行...
06-30 18:09
美股盘前 | Genmab A/S涨7.61%，Rocket Lab涨4.17%
Genmab A/S涨7.61%；Rocket Lab涨4.17%；Haleon PLC Sponsored ADR涨3.54%
06-30 16:10
